Skip to content

Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05327673
Acronym
AlloRé
Enrollment
100
Registered
2022-04-14
Start date
2022-07-31
Completion date
2027-03-31
Last updated
2022-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Brief summary

This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).

Interventions

OTHERquestionnaire

* quality of life score: FACT-BMT * decisional conflict scale * Discreet Choice Experiment questionnaire

Sponsors

Institut Paoli-Calmettes
CollaboratorOTHER
Centre Hospitalier Universitaire de la Réunion
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome * candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ; * Residing in Reunion Island * Age \>18 year old; * who accept or not allogeneic hematopoietic * Able to complete a questionnaire

Exclusion criteria

* Opposition to participation and collection of their data * Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)

Design outcomes

Primary

MeasureTime frame
Quality of life Functional Assessment of Cancer Therapy - Bone Marrow Transplantation questionnaire. (FACT-BMT questionnaire)24 months

Secondary

MeasureTime frameDescription
satisfaction with decision questionnaire24 months
decision regret scale24 months
fear of recurrence questionnaire24 months
preferences of patients questionnaire24 months
cost of treatment24 monthsimpact on patients and caregivers; impact on society

Countries

France

Contacts

Primary ContactLucie AUZANNEAU
lucie.auzanneau@chu-reunion.fr0262359949
Backup ContactPatricia MARINO
patricia.marino@inserm.fr04.91.22.35.02

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026